Werewolf Therapeutics (HOWL) Operating Expenses (2020 - 2026)

Werewolf Therapeutics (HOWL) has reported Operating Expenses for 7 consecutive years, with $13.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 21.09% year-over-year to $13.8 million in Q2 2026; TTM through Jun 2026 was $52.3 million, a 28.42% decrease from a year earlier, with the FY2025 full-year figure at $60.7 million, down 19.61% from the prior year.
• Operating Expenses was $13.8 million for Q2 2026 at Werewolf Therapeutics, up from $13.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $20.5 million in Q4 2022 and troughed at $9.4 million in Q4 2025.
• A 5-year average of $16.5 million and a median of $16.9 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 106.2% in 2022 and tumbled 53.72% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $20.5 million in 2022, then slipped by 29.32% to $14.5 million in 2023, then jumped by 40.69% to $20.3 million in 2024, then plunged by 53.72% to $9.4 million in 2025, then soared by 46.97% to $13.8 million in 2026.
• The last three Operating Expenses figures came in at $13.8 million (Q2 2026), $13.3 million (Q1 2026), and $9.4 million (Q4 2025), per Business Quant data.